Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by theo12on Dec 19, 2019 2:27pm
77 Views
Post# 30473608

RE:RE:RE:RE:RE:RE:RE:RE:estimates 2019

RE:RE:RE:RE:RE:RE:RE:RE:estimates 2019I am amazed!!!!    Because they worked harder,  they deserve bonuses and options.  WOW.  Don't they have a baisc salary for which they have to provide time and results, not just sit on a chair to warm it up.  Bonuses and options are rewards for exceptional results,  as good results are expected for the daily salary.  But in 2019,  I see only deficiencies  (value of the SP  which is the bottom line and the one that counts). Someone might work hard but deficiently, and deserves gratifications???
I remember, on the 2018 annual meeting, right at the start, a pause was made by the speaker to pinpoint that TH had reached that morning the value of 1 billion $.  The results of the last few months.  Le parquet en avant se ptait les bretelles. Then it was enjoyable to vote for bonuses and options. But I don't see any valid reason for gratifications for 2019. Maybe some other year after strong results,  but let's not forget that the base for those results is the  $ 14  SP of that 2018 annual meeting.   
Bullboard Posts